Expression of apoptosis protein inhibitor Apollon in breast cancer tissue and its clinical significance

doi:10.3877/cma. j. issn.1674-0807.2015.05.006

Abstract

Abstract:

Objective

To investigate the immunohistochemical expression of apoptosis protein inhibitor Apollon in breast cancer tissue and its clinical significance.

Methods

We retrospectively analyzed the female breast cancer tissue specimens from 66 cases treated in No.422 Hospital of PLA from January 2010 and December 2014. The expressions of Apollon, HER-2 and survivin were assessed immunohistochemically. The correlation of Apollon expression with HER-2 expression, survivin expression, tumor size and lymph node status was analyzed using Kendall rank correlation test.

Results

The positive rates of Apollon, HER-2 and survivin in breast cancer tissue were 59.1% (39/66),31.8% (21/66) and 39.4%(26/66), respectively. Apollon expression was significantly associated with HER-2 expression (tau-b=0.370, P=0.003), survivin expression(tau-b=0.292, P=0.018), tumor size (tau-b=0.322, P=0.009) and lymph node status (tau-b=0.424, P=0.001).

Conclusions

Apollon expression is associated with HER-2 expression, survivin expression, tumor size and lymph node status.Apollon may be a potential molecular marker in the development of breast cancer.

Key words: Breast neoplasms; Inhibitor of apoptosis proteins; Immunohistochemistry; Prognosis

Jianfa Chen, Zhiqiang Yue, Ming Fu, You Mo, Shurong Zhou. Expression of apoptosis protein inhibitor Apollon in breast cancer tissue and its clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(05): 312-315.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2015.05.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2015/V09/I05/312

Figures/Tables 2

References 24

[1]	Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China,2011[J]. Chin J Cancer Res,2015;27(1):2-12.
[2]	Pennati M, Millo E, Gandellini P, et al. RNA interferencemediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy [J]. Curr Top Med Chem,2012,12(2):69-78.
[3]	宫惠琳, 张锁平, 张冠军, 等. Survivin、MMP-2 在乳腺癌中的表达及其相关性研究[J]. 重庆医科大学学报, 2012,37(2):106-109.
[4]	曹丹霞, 何建蓉, 沈坤炜, 等. 激素受体和HER-2 及Ki-67预测乳腺癌新辅助化疗疗效价值的分析[J]. 中华肿瘤防治杂志,2012,19(13):1000-1003.
[5]	Cotter TG. Apoptosis and cancer:the genesis of a research field[J]. Nat Rev Cancer,2009,9(7):501-507.
[6]	Deveraux QL,Reed JC. IAP family proteins--suppressors of apoptosis[J]. Genes Dev,1999,13(3):239-252.
[7]	Hauser HP, Bardroff M, Pyrowolakis G, et al. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors[J]. J Cell Biol,1998,141(6):1415-1422.
[8]	Qiu XB, Goldberg AL. The membrane-associated inhibitor of apoptosis protein, BRUCE/Apollon, antagonizes both the precursor and mature forms of Smac and caspase-9[J]. J Biol Chem,2005,280(1):174-182.
[9]	Hao Y, Sekine K, Kawabata A, et al. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function[J]. Nat Cell Biol,2004,6(9):849-860.
[10]	Ismail EA, Mahmoud HM, Tawfik LM, et al. BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis[J]. Eur J Haematol,2012,88(2):118-127.
[11]	Low CG, Luk IS, Lin D, et al. BIRC6 protein, an inhibitor of apoptosis: role in survival of human prostate cancer cells[J].PLoS One,2013,8(2):e55837.
[12]	Wang L, Chen YJ, Hou J, et al. Expression and clinical significance of BIRC6 in human epithelial ovarian cancer[J].Tumour Biol,2014,35(5):4891-4896.
[13]	罗力亚, 刘风玲. HER2 /neu 在肿瘤中研究进展及抗HER2/neu 治疗[J]. 现代肿瘤医学, 2011,19 (12):2573-2576.
[14]	Barnes DM. c-erbB-2 amplification in mammary carcinoma[J]. J Cell Biochem Suppl,1993,17G:132-138.
[15]	董营,康丽花,关萌,等.乳腺癌患者术后辅助治疗的临床效果及其影响因素分析[J]. 吉林大学学报(医学版), 2015,41(3):636-642.
[16]	Song J, Su H, Zhou YY, et al. Prognostic value of survivin expression in breast cancer patients: a meta-analysis [J].Tumour Biol,2013,34(4):2053-2062.
[17]	陈建发,岳志强,傅明,等. 新辅助化疗前apollon 在乳腺癌组织中的表达及意义[J]. 南方医科大学学报, 2015,35(8):1201-1205.
[18]	李庆霞, 颜聪亚, 闫晓路, 等. 乳腺浸润性导管癌组织FGFR1 和Survivin 表达临床意义分析[J]. 中华肿瘤防治杂志,2013,20(17):1315-1318.
[19]	Zhang H, Jin F. HER-2 expression correlates with survivin in primary invasive ductal breast cancers[J]. Asian Pac J Cancer Prev,2010,11(5):1201-1204.
[20]	Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1[J]. Ann Oncol,2006,17(4):597-604.
[21]	Fuzhong T, Nan L, Jiajia G, et al. Clinical significance of the relationship between expression of survivin and effects of neoadjuvant chemotherapy in locally advanced breast cancer[J]. Gan To Kagaku Ryoho,2008,35(8):1319-1323.
[22]	Zhang M, Zhang X,Zhao S,et al. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer(TNBC) patients[J]. Target Oncol,2014,9(4):349-357.
[23]	张真,张小涛,于兰,等. 乳腺癌CD44v6 和Survivin 的表达与临床预后的相关性研究[J]. 中国肿瘤临床, 2011,38(14):835-838.
[24]	桑占发,王兴,齐玉新,等. survivin 在乳腺癌中的表达及其与Ki-67 和c-erbB-2 表达的关系[J]. 肿瘤防治研究,2010,37(7):773-776.

临床特征	例数	Apollon		相关系数	P值
临床特征	例数	阳性	阳性表达率(%)	相关系数	P值
HER-2
阳性	21	18	85.7%	0.370	0.003
阴性	45	21	46.7%	0.370	0.003
survivin
阳性	26	20	76.9%	0.292	0.018
阴性	40	19	47.5%	0.292	0.018
肿瘤大小
T_2-3	52	35	67.3%	0.322	0.009
T₁	14	4	28.6%	0.322	0.009
淋巴结状态
N_1-3	45	33	73.3%	0.424	0.001
N₀	21	6	28.6%	0.424	0.001

临床特征	例数	Apollon		相关系数	P值
临床特征	例数	阳性	阳性表达率(%)	相关系数	P值
HER-2
阳性	21	18	85.7%	0.370	0.003
阴性	45	21	46.7%	0.370	0.003
survivin
阳性	26	20	76.9%	0.292	0.018
阴性	40	19	47.5%	0.292	0.018
肿瘤大小
T_2-3	52	35	67.3%	0.322	0.009
T₁	14	4	28.6%	0.322	0.009
淋巴结状态
N_1-3	45	33	73.3%	0.424	0.001
N₀	21	6	28.6%	0.424	0.001

Please choose a citation manager

Content to export